[Table/Fig-2]:

Comparative results seen with S-1 experiments.

References	Level of evidence	Findings
Mori et al., 2006 [12]	III	S1 showed more therapeutic effect in prevention of gastric cancer.
Boku et al., 2009 [17]	I	S-1 was non-inferior to the continuous infusion of 5-FU in terms of Overall Survival (OS).
Shiozawa et al., 2009 [14]	I	Japanese randomized phase III trial (GC0301/TOP-002) conducted in 326 patients to compare S1 with S-1 plus irinotecan showed a significant response advantage for combination arm (41.5% vs. 26.9%, p=0.35).
Zang et al., 2009 [15]	I	In multicenter phase II clinical trial, the efficacy of oral S1 with biweekly regimen paclitaxel showed that response rate was good (43.6%) with greater survival days with this treatment regimen.
Baba et al., 2009 [16]	I	A phase I trial applying increasing doses of oral administration of S-1 (65-80 mg/mL) for 21 days and increasing doses of CDDP (60-80 mg/mL) on day 22, every 35 days, was conducted to determine MTD and the recommended dose (RD) for the phase II studies. Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer showed that this sequential administration of S-1 and CDDP every 35 days was tolerable and warranted a phase II trial.